IRADIMED CORPORATION to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
IRADIMED (NASDAQ: IRMD), a leading provider of innovative MRI-compatible medical devices, announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference. The event will take place on October 9, 2024, at the Metropolitan Club in New York.
Iradimed's CFO, Jack Glenn, will be hosting one-on-one meetings with investors during the conference. This participation demonstrates Iradimed's commitment to engaging with the investment community and showcasing its innovative products in the healthcare sector.
The conference provides an excellent platform for Iradimed to connect with potential investors and discuss its advancements in MRI-compatible medical devices. It also offers an opportunity for the company to highlight its market position and growth strategies in the healthcare technology industry.
IRADIMED (NASDAQ: IRMD), un fornitore leader di dispositivi medici innovativi compatibili con la risonanza magnetica, ha annunciato la sua partecipazione al 3° Convegno Annuale sulle Opportunità Sanitarie ROTH. L'evento si terrà il 9 ottobre 2024 presso il Metropolitan Club di New York.
Il CFO di Iradimed, Jack Glenn, ospiterà incontri individuali con gli investitori durante la conferenza. Questa partecipazione dimostra l'impegno di Iradimed a interagire con la comunità degli investimenti e a mettere in evidenza i suoi prodotti innovativi nel settore sanitario.
La conferenza offre un'ottima piattaforma per Iradimed per connettersi con potenziali investitori e discutere i suoi progressi nei dispositivi medici compatibili con la risonanza magnetica. Offre anche l'opportunità per l'azienda di evidenziare la sua posizione sul mercato e le strategie di crescita nell'industria della tecnologia sanitaria.
IRADIMED (NASDAQ: IRMD), un proveedor líder de dispositivos médicos innovadores compatibles con MRI, anunció su participación en la 3ª Conferencia Anual de Oportunidades de Salud ROTH. El evento tendrá lugar el 9 de octubre de 2024 en el Metropolitan Club de Nueva York.
El CFO de Iradimed, Jack Glenn, realizará reuniones individuales con los inversores durante la conferencia. Esta participación demuestra el compromiso de Iradimed con la comunidad inversora y la presentación de sus productos innovadores en el sector de la salud.
La conferencia proporciona una excelente plataforma para que Iradimed se conecte con posibles inversores y discuta sus avances en dispositivos médicos compatibles con MRI. También ofrece una oportunidad para que la empresa destaque su posición en el mercado y las estrategias de crecimiento en la industria de la tecnología sanitaria.
IRADIMED (NASDAQ: IRMD), 혁신적인 MRI 호환 의료 장치의 선도적 공급업체가 제3회 연례 ROTH 헬스케어 기회 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 10월 9일 뉴욕의 메트로폴리탄 클럽에서 열립니다.
IRADIMED의 CFO인 Jack Glenn은 컨퍼런스 기간 동안 투자자들과 일대일 미팅을 주최할 예정입니다. 이번 참여는 투자 커뮤니티와 소통하고 헬스케어 분야의 혁신적인 제품을 선보이려는 IRADIMED의 의지를 보여줍니다.
컨퍼런스는 IRADIMED가 잠재 투자자와 연결하고 MRI 호환 의료 장치의 발전에 대해 논의할 수 있는 훌륭한 플랫폼을 제공합니다. 또한 회사가 시장에서의 위치와 헬스케어 기술 산업 내 성장 전략을 부각할 수 있는 기회를 제공합니다.
IRADIMED (NASDAQ: IRMD), un fournisseur leader de dispositifs médicaux innovants compatibles avec l'IRM, a annoncé sa participation à la 3ème Conférence Annuelle sur les Opportunités de Santé ROTH. L'événement se déroulera le 9 octobre 2024 au Metropolitan Club de New York.
Le CFO d'Iradimed, Jack Glenn, animera des réunions individuelles avec les investisseurs lors de la conférence. Cette participation démontre l'engagement d'Iradimed envers la communauté des investisseurs et la présentation de ses produits innovants dans le secteur de la santé.
La conférence offre une excellente plateforme à Iradimed pour établir des contacts avec des investisseurs potentiels et discuter de ses avancées en matière de dispositifs médicaux compatibles avec l'IRM. Elle offre également l'opportunité à l'entreprise de mettre en avant sa position sur le marché et ses stratégies de croissance dans l'industrie de la technologie de la santé.
IRADIMED (NASDAQ: IRMD), ein führender Anbieter innovativer MRT-kompatibler Medizinprodukte, gab seine Teilnahme an der 3. jährlichen ROTH Gesundheitschancen-Konferenz bekannt. Die Veranstaltung findet am 9. Oktober 2024 im Metropolitan Club in New York statt.
Der CFO von Iradimed, Jack Glenn, wird während der Konferenz Einzelgespräche mit Investoren führen. Diese Teilnahme zeigt Iradimeds Engagement für den Austausch mit der Investoren-Community und die Präsentation seiner innovativen Produkte im Gesundheitssektor.
Die Konferenz bietet eine hervorragende Plattform für Iradimed, um mit potenziellen Investoren in Kontakt zu treten und über seine Fortschritte bei MRT-kompatiblen Medizinprodukten zu diskutieren. Sie bietet auch die Möglichkeit für das Unternehmen, seine Marktposition und Wachstumsstrategien in der Gesundheits-Technologie-Industrie hervorzuheben.
- None.
- None.
WINTER SPRINGS, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it will participate in the 3rd Annual ROTH Healthcare Opportunities Conference.
Iradimed’s CFO, Jack Glenn, will host one-on-one meetings with investors at the 3rd Annual ROTH Healthcare Opportunities Conference at the Metropolitan Club in New York on October 9, 2024.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.
We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many dangers and problems during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design, allowing it to travel with the patient from their critical care unit to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI-compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.
For more information, please visit www.iradimed.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, or the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as “believe,” “intend,” “expect,” “anticipate,” “plan,” “potential,” “continue,” or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks, and uncertainties are discussed in Iradimed’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown uncertainties and other factors that are, in some cases, beyond Iradimed’s control, which could and likely will materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects Iradimed’s current views concerning future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Iradimed assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available. The contents of any website referenced in this press release are not incorporated by reference herein.
Media Contact:
Jack Glenn
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com
This press release was published by a CLEAR® Verified individual.
FAQ
When and where is IRADIMED (IRMD) participating in the ROTH Healthcare Opportunities Conference?
Who will represent IRADIMED (IRMD) at the ROTH Healthcare Opportunities Conference?
What type of meetings will IRADIMED (IRMD) be hosting at the ROTH Healthcare Conference?
What is IRADIMED 's (IRMD) main business focus?
